Providing next-generation regenerative medicine.
Medical advances have led to a welcome increase in life expectancy. However, this has led to a rise in age-related diseases and healthcare costs. In addition to the ageing society, increasingly active younger demographics are also prone to trauma, injury or disease, all resulting in tissue deterioration for which there are limited answers.
Renovos, a regenerative medicine company, is pioneering a nanoclay gel technology platform, Renovite®, for medical applications to address the unmet need for long term tissue regeneration, offering safer, more economic clinical solutions for health systems, and better outcomes for patients.
What’s the innovation?
Renovos is transforming orthopaedics and regenerative medicine through the pioneering use of nanoclay gels from world-class stem cell research.
The Renovite nanoclay gel technology represents easier to use than conventional medicine delivery methods and has the potential to address the unmet need for long term tissue regeneration, offering safer, more economic clinical solutions for health systems and better outcomes for patients.
What are you looking to get from #VFS20?
At this years #VFS20 we are looking to put out our product development, and looking to meet with investors and potential collaborators.